INTRODUCTION
Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease characterized by sacroiliac joint and axial skeletal involvement 1 . It is thought that genetic, environmental, and immunological factors are effective in the pathogenesis of this disease. Best known genetic predisposition factor is HLA-B27 (human leucocyte antigen), but its association with the pathogenesis of this disease is still not exactly known 2 . The risk of occurrence of AS in people who are positive for HLA-B27 is 1.3% 3 . This also suggests that some genes other than HLA-B27 and some environmental factors are also lying under the development of AS. MEFV gene, which is responsible for activations of many rheumatic diseases, may also have a role in the development of AS 4 .
MEFV gene, which is responsible for Familial Mediterranean Fever (FMF), is located in the 13.3 region of 16th chromosome (16p), formed of 10 exons and 15 kb of 3505 nucleotides, and expresses a weak transcript of 3.7 kb and encodes a protein of 781 aminoacids 5 . It encodes a protein named pyrine/marenostrine that synthesized in the cytosols of neutrophils, eosinophilia, and activated monocytes. Pyrine protein is thought to play a role in inhibiting the neutrophil activity and inflammation during the FMF episodes 6 .
Carrying the heterozygous MEFV mutations in FMF is suspected for increased clinical and subclinical inflammation 7 , and disease modification for increased inflammatory response in the development or during the course of the chronic inflammatory diseases. In a study that was conducted for determining the effects of MEFV mutation on disease activity and inflammation, it was found that these parameters were both increased in the presence of MEFV mutations in patients with RA. It is unclear that how the MEFV mutation increases the disease severity in RA, but this was thought to be associated with pyrine functions 8 . Thus, MEFV gene mutations were found to have impact on chronic inflammatory diseases other than RA, such as Ulcerative Colitis (UC), Behcet's disease, multiple sclerosis, Henoch-Schönlein Purpura (HSP), and Chrohn Disease [9] [10] [11] [12] . Patients that have the inflammatory load of these diseases are thought to be more vulnerable for more severe disease in the presence of MEFV mutations. We aimed in this study to investigate the presence of MEFV gene mutations in AS, which is also a chronic inflammatory disease, and to determine its associations with the disease activity.
MATERIAL AND METHODS
This study included 34 patients, whom were diagnosed according to the Modified New York Diagnostic Criteria 13 , and 35 healthy volunteers as control group. Patients that met criteria for other spondyloarthopathies, having suspected history of FMF, or having FMF in family history were excluded from the study. All patients informed about the study and consents were taken. After inclusion, venous blood samples were taken from the patients in tubes containing 10 mL of EDTA.
Age, gender, disease onset and duration, medication, family history, and peripheral joint involvement were noted for each patient. Disease activity was evaluated by laboratory parameters as ESR and CRP, and clinical parameters as BASDAI, BASMI and BASFI. Patients and healthy controls were assessed for prevalent 12 MEFV mutations. Patients with AS were separated into two groups according to the presence of MEFV mutation, or not. Disease activity in the preceding 1 week was evaluated by BASDAI. Axial skeletal pain, morning stiffness, peripheral joint pain, non-joint pain and fatigue were evaluated by the patients by a VAS scale of 1 to 10, and arithmetic means were calculated. Mean score of two questions that evaluates morning stiffness was calculated and summed with the other questions. BASDAI values greater than 4/10 were regarded as active disease.
Genetic analysis
Twelve prevalent mutations for MEFV gene were studied from the 10 mL of blood samples. These 12 mutations (E148Q, P369S, F479L, M680I (G/C), M680I (G/A), 1692del, M694V, M694I, K695R, V726A, A744S ve R761H) were analyzed in the Genetics Department by using reverse hybridization stripe assay technique (Vienna Lab) according to the directions of the manufacturer.
Statistical analysis
Data was evaluated by SPSS Ver. 14.0. Chi-square test, Mann-Whitney-U test, and Fisher's Exact Chi-Square test were used for the statistical analyses. Values were presented as arithmetic mean±standard deviation, number of cases and % in the tables. Statistical significance level was considered as 0.05 in all analyses.
RESULTS
All participants were separated into two groups as patients and controls, and patients were then separated into two groups again according to the presence of MEFV mutations. Mean ages of patients were 39.97±11.33 years, and 41.25±9.9 for controls. Difference of the ages of patients and controls was not statistically significant (t=0.50, p=0.618). Female to male ratio were 9 (26.5%) to 25 (73.5%), and 10 (28.6%) to 25 (71.4%) in patient and control groups, respectively. Gender distribution between these two groups was similar (X 2 =0.03; p=0.845). Table 2 . Peripheral joint involvement was similar between patients with and without MEFV mutations (p>0.05), but involvement rates were higher in MEFV positive patients. Distribution of MEFV mutations according to peripheral joint involvement were presented in Table 3 .
When the patients with AS were distributed into two groups according to MEFV positivity, 14 patients constituted the MEFV positive group, and 7 of them (50%) had E148Q, 4 of them (28.6%) had M694V mutations, and this was found to be statistically significant (p=0.001; p=0.022, respectively).
BASDAI values were 5.12 ± 1.27 and 3.05 ± 1.34 in patients with and without MEFV mutations, respectively. The difference between the groups was statistically significant (p<0.05). Mean BASDAI values in these patient groups were presented in Figure 1 .
DISCUSSION
Although the etiopathogenesis of AS is not exactly known, generally genetic factors are suspected. Because the majority of the autoimmune diseases are polygenic in nature, and genetic polymorphisms increase the vulnerability to the disease 15 , MEFV gene mutations are investigated for AS in this study.
Genetic studies showed that HLA-B27 had a contribution of 30-40%, and MHC region that also includes HLA had a contribution of 50% to the total genetic vulnerability 16 . Genome wide association studies, which were conducted for determining the other genes that contributes to the vulnerability, defined many non-HLA nominate gene regions. Most important non-HLA region that contributes to the AS pathogenesis was reported by these association studies as IL-1 gene family located in 2nd chromosome. This region includes Il-1α, IL-1β and IL-RA genes, and large scaled association studies confirmed the relationships between the polymorphisms of this region and the AS 17 .
It was previously reported that mutations of MEFV gene that is responsible for FMF are increased in patients with AS, and carrying the heterozygous mutations of this gene is associated with increased erythrocyte sedimentation rate, peripheral arthritis, and repeated oral ulcers. The association of MEFV gene mutations and increased IL-1β activity also confirms the association between AS and IL-1 polymorphisms 18 . Durmuş et al 19 . found in their study that frequency of MEFV mutations were similar in AS and control groups, but presence of MEFV mutation in patients with AS increased the disease severity. This was explained by the increased inflammatory response could cause more severe disease 19 . Despite of the previous studies, we found the MEFV mutations in a higher frequency. We also checked for laboratory parameters in control group, and both the laboratory parameters and BASDAI values that show the disease
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Çınar et al 20 . conducted a longitudinal clinical study in 95 patients with AS, and they could not determine any significant differences for clinical and laboratory parameters between patients that have MEFV mutations or not. They also did not find any E148Q mutations 20 . Despite of their study, we found the most frequent mutation was E148Q (50%) in patients with MEFV mutations and these patients had increased ESR, CRP and BASDAI values. Determination of this mutation in a significantly higher frequency may be related to geographical differences.
The association between MEFV mutations and arthritic diseases were suggested by Booth et al 21 . in their study that reported higher frequencies of E148Q mutations than normal levels in white and Indian patients with inflammatory arthritis and amyloidosis. E148Q is a mutation at 2nd exon and it is seen widely in normal population, and also thought to be a mutation with low penetration. But a previous study reported that combined heterozygosity of V726A-E148Q can cause amyloidosis 22, 23 . Rabinovich et al 8 . also determined E148Q as the most frequent mutation in patients with RA, and reported severe disease in this case. Our patients with AS and MEFV mutations also had higher frequencies of E148Q mutations, and colchicine treatment may be important in these patients in regard of amyloidosis.
As a conclusion, we found that MEFV mutation frequency is similar with control group, but disease severity may increase in patients with AS and MEFV mutations. Further studies are needed when the geographical factors that can affect the MEFV mutation carriers taken into consideration. We think that determination of new gene regions that modifies the severity of AS, which can be a progressive and deteriorating disease, will yield new explanations in the pathophysiology of the disease, and will help develop new treatment protocols.
